Neurocrine biosciences announces ceo succession plan

Board of directors appoints kyle gano, ph.d., chief business development and strategy officer, as ceo-elect, effective october 11, 2024 kevin gorman, ph.d.

NBIX Ratings Summary

NBIX Quant Ranking